Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment.
Front Dement August 4, 2025 Xenia Androni, Rachel J. Boyd, Paul B. Rosenberg et al. 4 citations
Alzheimer's disease (AD) is characterized by a long preclinical phase lasting more than a decade before the onset of its clinical phase of mild cognitive impairment (MCI) or dementia. Recent advances in psychedelic research underscore numerous neuroplastogenic and anti-inflammatory alterations induced by these compounds, making them promising therapeutic candidates for AD. In this mini review,...